LivaNova plc (NASDAQ: LIVN) reported Q2 EPS of $1.01, $0.19 better than the analyst estimate of $0.82. Revenue for the quarter came in at $321.4 million versus the consensus estimate of $315.6 million.

2017 Guidance

On May 2, 2017, LivaNova announced the acquisition of Caisson Interventional, LLC (Caisson), in support of LivaNova’s strategic growth initiatives. As a result, certain guidance for full-year 2017 was revised at that time.

LivaNova reiterates that worldwide net sales for full-year 2017 will remain between 1 and 3 percent growth on a constant currency basis, and adjusted diluted earnings per share for 2017 will remain in the range of $3.10 to $3.30. The Company reiterates that adjusted cash flow from operations, excluding integration, restructuring and 3T remediation payments, will remain in the range of $170 to $190 million in 2017.

For the second quarter of 2017, worldwide sales were $321.4 million, an increase of 0.1 percent on a reported basis and an increase of 1.4 percent on a constant currency basis, as compared to the same quarter of the previous year. On the basis of U.S. Generally Accepted Accounting Principles (GAAP), second quarter 2017 earnings per share were $0.98. Second quarter 2017 adjusted diluted earnings per share were $1.01.

GUIDANCE:

LivaNova plc sees FY2017 EPS of $3.10-$3.30, versus the consensus of $3.11.

For earnings history and earnings-related data on LivaNova plc (LIVN) click here.